INNOVAFEED raises €51 million while cutting 60 jobs: the paradox of industrial scale-up

While the French insect protein sector remains marked by the collapse of Ynsect, Innovafeed has announced a €51 million funding round backed by its existing shareholders. At the same time, the company is moving forward with plans to eliminate around sixty positions. At first glance, the sequence may appear contradictory. In reality, it illustrates the transition of a deeptech company from a research-driven phase to one focused on industrial operations and commercial execution.

Innovafeed has secured €51 million in fresh financing from its historical investors, including Creadev, QIA, Temasek, ABC Impact, ADM and French Food Capital. Simultaneously, the company plans to cut approximately sixty jobs, with two-thirds of the reductions affecting its historic site in Gouzeaucourt.

In an ecosystem where fundraising is typically associated with hiring and accelerated growth, the announcement may seem counterintuitive. It reflects the reality of a company that believes it has passed the riskiest stage of its development and is now reorganising its resources around industrial production.

For years, Innovafeed and Ynsect have been the two leading French representatives of the insect protein industry. Both companies raised hundreds of millions of euros to build unprecedented industrial capacity. However, the difficulties encountered by Ynsect have fundamentally changed how the sector is viewed. Investors are no longer evaluating technological promises or theoretical production capabilities alone. They are increasingly looking for evidence of industrial execution and economic competitiveness.

This is precisely the narrative Innovafeed is putting forward. Since its last funding round in 2022, the company says it has achieved three major milestones: producing more than 15,000 tonnes of proteins and oils at its Nesle facility, increasing volumes tenfold, and reducing production costs by a factor of seven. Innovafeed also claims to have reached an industrial scale three times larger than that of the world’s second-largest player in the sector.

The company now argues that it has demonstrated the robustness of its industrial platform. Its Nesle site is presented as fully operational and capable of producing competitive volumes at scale.

Against this backdrop, the €51 million financing is no longer intended to fund the construction of a new facility or the development of breakthrough technology. Instead, Innovafeed says the capital will be used to accelerate the commercial deployment of its Hilucia™ product range, develop new applications, and continue improving its industrial equipment.

This change of phase also explains the announced reorganisation. Over the past decade, Innovafeed invested heavily in research and development to build its technology, optimise production processes and validate product performance. The company has now decided to discontinue its zootechnical R&D activities at Gouzeaucourt and partially integrate them into its Nesle operations.

The move may appear paradoxical, but it is characteristic of many industrial companies reaching maturity. The skills required to invent a technology are not necessarily the same as those needed to operate large-scale industrial assets. As production processes stabilise, priorities shift toward manufacturing, operational efficiency, logistics and commercial development.

For the insect protein industry, this evolution may ultimately prove more significant than the funding round itself. After years spent convincing investors, building factories and demonstrating technological feasibility, the sector is entering a new phase: proving that it can generate sustainable economic value.

From that perspective, the €51 million raised by Innovafeed looks less like a traditional growth financing and more like a vote of confidence in an industrial model that believes it has passed its most important test: achieving scale.